<DOC>
	<DOCNO>NCT00002393</DOCNO>
	<brief_summary>The purpose study see safe effective add DMP 266 anti-HIV treatment program indinavir nucleoside reverse transcriptase inhibitor ( NRTIs ) .</brief_summary>
	<brief_title>A Study Indinavir Taken With Without DMP 266</brief_title>
	<detailed_description>In double-blind , placebo-controlled study , 300 patient randomize 1 2 reverse transcriptase inhibitor choice plus blinded therapy Arm A B follow : Arm A : DMP 266 placebo plus indinavir . Arm B : DMP 266 plus indinavir . After 16 week , patient may switch NRTI portion regimen meet treatment failure criterion . After completion 24-week period , patient option continue open-label DMP 266 indinavir .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Indinavir</mesh_term>
	<criteria>Inclusion Criteria Patients must : CD4+ cell count least 50 cells/mm3 . HIV RNA level least 10,000 copies/ml reverse transcriptase polymerase chain reaction ( RTPCR , Amplicor test kit ) screening . Signed , inform consent parent legal guardian patient le 18 year age . Exclusion Criteria Prior Medication : Excluded : DMP 266 . Other nonnucleoside reverse transcriptase inhibitor . Required : One two NRTIs ( except ZDV d4T combination ) minimum 8 week , within 12 week prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 1998</verification_date>
	<keyword>Placebos</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Indinavir</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>efavirenz</keyword>
</DOC>